ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,213.30
-0.22%
S&P ASX All Technology
3,719.30
-1.15%
Brent Oil
79.525
-0.22%
US Dollar vs AUD
1.61202
-0.21%
Bitcoin
96,703.53
0.21%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE

  6. Penumbra Inc (PEN) Share Price

Penumbra Inc

Penumbra Inc (PEN)

Peninsula Energy Ltd
Pennant International Group Plc
PBF Energy Inc
252.89
5.96
(2.41%)
Closed 15 January 8:00AM
Delayed by 15 minutes
252.89
0.00
( 0.00% )
Pre Market: 9:19PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
252.89
Bid
-
Offer
-
Volume
28
0.00 Day's Range 0.00
148.00 52 Week Range 277.34
Market Cap
9.706B
Previous Close
252.89
Open
-
Last Trade
1
@
252.51
Last Trade Time
21:19:41
Financial Volume
-
VWAP
-
Average Volume (3m)
373,040
Shares Outstanding
38,379,199
Dividend Yield
-
PE Ratio
106.71
Earnings Per Share (EPS)
2.37
Revenue
1.06B
Net Profit
90.95M

About Penumbra Inc

Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurova... Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for the neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
www.penumbrainc.com
Headquarters
Dover, Delaware, USA
Founded
-
Penumbra Inc is listed in the Surgical,med Instr,apparatus sector of the New York Stock Exchange with ticker PEN. The last closing price for Penumbra was US$252.89. Over the last year, Penumbra shares have traded in a share price range of US$ 148.00 to US$ 277.34.

Penumbra currently has 38,379,199 shares in issue. The market capitalisation of Penumbra is US$9.71 billion. Penumbra has a price to earnings ratio (PE ratio) of 106.71.

Ask ADVFN Intelligence (AI)

Penumbra (PEN) Options Flow Summary

PEN Options Flow

Overall Flow

Bearish

Net Premium

-7k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

PEN Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

07 January 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

07 January 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

04 January 2025
Edgar (US Regulatory)

Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire ALAMEDA, Calif., Dec. 30, 2024 ALAMEDA, Calif., Dec. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN...

31 December 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

28 December 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

24 December 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

18 December 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

18 December 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

18 December 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

04 December 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.4150.164372710169252.475258.52235.02445393252.10191926CS
46.8152.76948084933246.075260.875222.59420294244.83743062CS
1247.5323.1447214647205.36260.875199.01373040237.69745111CS
2662.0632.5210920715190.83260.875148412442208.83653347CS
52-1.99-0.780759573132254.88277.34148375016212.33581119CS
15617.977.64941256598234.92348.67114.865358537219.0152826CS
26094.2459.4011976048158.65348.67114.865349866220.39967114CS

PEN - Frequently Asked Questions (FAQ)

What is the current Penumbra share price?
The current share price of Penumbra is US$ 252.89
How many Penumbra shares are in issue?
Penumbra has 38,379,199 shares in issue
What is the market cap of Penumbra?
The market capitalisation of Penumbra is USD 9.71B
What is the 1 year trading range for Penumbra share price?
Penumbra has traded in the range of US$ 148.00 to US$ 277.34 during the past year
What is the PE ratio of Penumbra?
The price to earnings ratio of Penumbra is 106.71
What is the cash to sales ratio of Penumbra?
The cash to sales ratio of Penumbra is 9.17
What is the reporting currency for Penumbra?
Penumbra reports financial results in USD
What is the latest annual turnover for Penumbra?
The latest annual turnover of Penumbra is USD 1.06B
What is the latest annual profit for Penumbra?
The latest annual profit of Penumbra is USD 90.95M
What is the registered address of Penumbra?
The registered address for Penumbra is 3500 S DUPONT HWY, DOVER, DELAWARE, 19901
What is the Penumbra website address?
The website address for Penumbra is www.penumbrainc.com
Which industry sector does Penumbra operate in?
Penumbra operates in the SURGICAL,MED INSTR,APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BWNBBabcock and Wilcox Enterprises Inc
US$ 24.20
(18.63%)
14
TEAFTortoise Sustainable and Social Impact Term Fund
US$ 13.99
(17.07%)
3
EHABEnhabit Inc
US$ 8.98
(16.02%)
7
BARKBARK Inc
US$ 2.24
(14.29%)
54
NGLNGL Energy Partners LP
US$ 6.23
(13.69%)
11
NLNL Industries Inc
US$ 5.31
(-29.39%)
4
GHLDGuild Holdings Company
US$ 10.01
(-21.31%)
18
BXMXNuveen S&P 500 Buy Write Income Fund
US$ 11.01
(-19.69%)
1
LICYLi Cycle Holdings Corp
US$ 1.27
(-16.45%)
391.22k
AFBAllianceBernstein National Municipal Income Fund Inc
US$ 9.01
(-15.64%)
6
QBTSD Wave Quantum Inc
US$ 5.34
(12.90%)
4.6M
SESSES AI Corporation
US$ 0.8561
(4.36%)
1.1M
IONQIonQ Inc
US$ 29.99
(1.63%)
1.05M
FUBOfuboTV
US$ 3.84
(0.79%)
458.02k
LICYLi Cycle Holdings Corp
US$ 1.27
(-16.45%)
391.22k

PEN Discussion

View Posts
@LaughinPaulRyan @LaughinPaulRyan 4 years ago
... ALL NEWS IS GOOD? ... $PEN



CNBC's Scott Wapner reports on why Quintessential Capital Management is shorting Penumbra and why it's questioning the safety of its medical devices.

👍️0
@LaughinPaulRyan @LaughinPaulRyan 4 years ago
QCM legal team filed detailed reports with allegations of misconduct with FDA, SEC and other institutions urging thorough investigation
Deceptive behavior would point to lack of integrity unworthy of management leading $10bn healthcare company and may explain Jet7 crisis leading to multiple deaths, injuries
QCM calls on Adam Elsesser, Arani Bose to resign at once if allegations confirmed
Situation constitutes existential threat to Penumbra’s viability as a public company
👍️0
@LaughinPaulRyan @LaughinPaulRyan 4 years ago
Executive Summary

Large portion of scientific literature produced by Penumbra appears authored by fake character in sophisticated, multi-year deception
Fake character seems fabricated by Penumbra’s management attempting to hide involvement in research with significant undisclosed conflicts of interest
Conflicted research used extensively to market products to healthcare providers, to support FDA applications and to promote stock in IPO
Legal advisers: behavior, if confirmed, may constitute serious fraud threatening revocation of FDA clearances, SEC enforcement and litigation from clients
👍️0
davidsson10 davidsson10 4 years ago
https://www.qcmfunds.com/penumbra-and-its-killer-catheter/?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link
👍️0
@LaughinPaulRyan @LaughinPaulRyan 4 years ago
... ROFLMFAO ... $PEN

Penumbra Inc
Penumbra, Inc. designs, develops, manufactures, and markets medical devices. The Company offers peripheral vascular and neurovascular devices that help patients suffering from stroke and other neurovascular diseases. Penumbra operates in the United States.
CURRENT PRICE

PEN:US197.48USD-26.54-11.85%AS OF 10:55 AM EST 12/08/2020
👍️0
TREND1 TREND1 9 years ago
IPO INFO

http://www.marketwatch.com/tools/ipo-calendar
👍️0
TREND1 TREND1 9 years ago
IPO NOW HAS SYMBOL
Penumbra PEN
👍️0
TREND1 TREND1 9 years ago
IPO should be out soon.
no symbol yet.
👍️0

Your Recent History

NYSE
PEN
Penumbra
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads